A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

The Car-T cell therapy was tested on patients with B-cell leukaemia and lymphoma - rare types of blood cancers - that affect the bone marrow and the lymphatic system.

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...